We know that, Lubiprostone (rINN, marketed under the trade name Amitiza) is a medication used in the management of chronic idiopathicconstipation and irritable bowel syndrome. It was approved by the U.S. Food and Drug Administration (FDA) for this purpose on 31 January 2006.
Sucampo announces positive results from lubiprostone phase 3 trial on OBD: Sucampo Pharmaceuticals, Inc. today announced positive top-line results from an open-label phase 3 clinical trial designed to evaluate the long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction (OBD) patients with chronic, non-cancer-related pain.
No comments:
Post a Comment